Dr. Douglas K. Hawley, MD

Expert Publications

• Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival.
• Ammonium and potassium cation exchange resin in treatment of congestive heart failure.
• Mechanistic studies of transcription arrest at the adenovirus major late attenuation site. Comparison of purified RNA polymerase II and washed elongation complexes.
• Kinetic analysis of yeast TFIID-TATA box complex formation suggests a multi-step pathway.
• TFIID binds in the minor groove of the TATA box.
• Concurrent radiotherapy and chemotherapy for locally advanced non-small-cell cancer of the lung. Report of a clinical trial and review of the literature.
• In vitro analysis of a transcription termination site for RNA polymerase II.
• Separation and partial characterization of three functional steps in transcription initiation by human RNA polymerase II.
• Functional steps in transcription initiation and reinitiation from the major late promoter in a HeLa nuclear extract.
• Functional and physical characterization of transcription initiation complexes in the bacteriophage lambda OR region.
• Hemoglobin of mice with radiation-induced mutations at the hemoglobin loci.
• Hemoglobin of mice with radiation-induced mutations at the hemoglobin loci.
• Mechanism of activation of transcription initiation from the lambda PRM promoter.
• The effect of a lambda repressor mutation on the activation of transcription initiation from the lambda PRM promoter.
• Compilation and analysis of Escherichia coli promoter DNA sequences.

Media Releases

Get to know Hematologist-Oncologist Dr. Douglas K. Hawley, who served patients in Ohio.

Dr. Hawley is a highly trained hematologist-oncologist who is retired from practice. During his active years on the job, he served as one of the five founding physicians at OHC, one of the nation’s largest oncology groups and the Tri-state’s only remaining independent oncology practice.

His areas of interest included Hodgkin’s disease, hematologic malignancies, sickle cell disease, lung cancer, breast cancer, melanoma, other solid tumors, and unusual diseases.

In a letter sent to his patients, he explained, “I love what I do now; I am as enthusiastic as I was 30 years ago when I first started my practice. But, as I turn 65 years old this coming year, I worry that the 18 hour days, missed meals and missed sleep are becoming an increasing threat to my good health. Although I would love to do this until age 90, I just don’t think it’s realistic.”

After graduating with his medical degree from the University of Cincinnati College of Medicine in 1979, Dr. Hawley went on to further his training. He performed his residency in internal medicine and his fellowship in hematology at University of Cincinnati Medical Center in 1982 and 1985, respectively. 

As a testament to his success, the doctor is board-certified in internal medicine, hematology, and medical oncology by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

Since April of 2015, Dr. Hawley has been serving as the Director of the Associate Hematology Oncology Fellowship Program at the University of Cincinnati College of Medicine. He is also a Clinical Associate Professor of Medicine at the said establishment. 

Among his professional affiliations, he is an active member of the American College of Physicians, the American Society of Clinical Oncology, and the American Society of Hematology.

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

Recommended Articles

• Ovarian Cancer Vaccine Development: An Update

  OncBioMune Pharmaceuticals, a clinical-stage bio-pharmaceutical company, is advancing its developments in vaccine technology to help boost the immune system to target cancer cells without causing harm to the patient. They have worked on prostate cancer vaccines and are working on ovarian cancer...

• What is Hodgkin's Lymphoma?

  Hodgkin’s lymphoma is the cancer of the lymphatic system, which is a part of the immune system. The lymphatic system is very important in that it is involved in the production of the white blood cells that fight against disease causing agents, like bacteria, fungi, and viruses. In this cancer,...

• BRCA Gene Risk Status Identified for Ovarian Cancer

  It is well-known in the medical community that a specific genetic mutation can increase your risk of getting ovarian cancer and breast cancer. These genes are commonly known as BRCA1 and BRCA 2. While it is more likely that you’ll get ovarian cancer if you happen to have this genetic abnormality,...

• What Primary Care Providers Need to Know About Ovarian Cancer

  In the United States, there will be 22,440 women diagnosed with ovarian cancer in 2017 and over half of those cases will be fatal, according to the American Cancer Society. For women, ovarian cancer is the fifth leading cause of cancer deaths. And a woman’s risk of developing ovarian cancer in her...

• The Unspoken Hardships of Breast Cancer and How to Overcome Them

  Receiving a cancer diagnosis can be hard enough, let alone having to deal with the financial burden of treatment. In 2010 in the United States, the cost of treating breast cancer was over $16 billion dollars. By 2020, this number is expected to reach up to $20.5 billion.According to the NCI, the...

• Why We Can’t Treat All Ovarian Cancer the Same Way

  Over the last three decades, ovarian cancer survival rates have seen very little improvement. The current five-year survival rate for ovarian cancer is 43%, a low percentage that is a result of the fact that this type of cancer is difficult to detect and often goes undiagnosed until it has reached...